| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5256 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2752 | 2020 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1325 | 2021 |
| Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... The Lancet 397 (10282), 1351-1362, 2021 | 734 | 2021 |
| Vaccines for COVID-19 JS Tregoning, ES Brown, HM Cheeseman, KE Flight, SL Higham, ... Clinical & Experimental Immunology 202 (2), 162-192, 2020 | 305 | 2020 |
| Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) A Flaxman, NG Marchevsky, D Jenkin, J Aboagye, PK Aley, B Angus, ... The Lancet 398 (10304), 981-990, 2021 | 269 | 2021 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial J Frater, KJ Ewer, A Ogbe, M Pace, S Adele, E Adland, J Alagaratnam, ... The lancet HIV 8 (8), e474-e485, 2021 | 215 | 2021 |
| Oxford COVID Vaccine Trial Group Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... Lancet 397 (10269), 99-111, 2021 | 133 | 2021 |
| COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study JL Alexander, NA Kennedy, H Ibraheim, S Anandabaskaran, A Saifuddin, ... The lancet Gastroenterology & hepatology 7 (4), 342-352, 2022 | 126 | 2022 |
| T-cell immunophenotyping distinguishes active from latent tuberculosis KM Pollock, HS Whitworth, DJ Montamat-Sicotte, L Grass, GS Cooke, ... The Journal of infectious diseases 208 (6), 952-968, 2013 | 120 | 2013 |
| Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial KM Pollock, HM Cheeseman, AJ Szubert, V Libri, M Boffito, D Owen, ... EClinicalMedicine 44, 2022 | 94 | 2022 |
| Oxford COVID Vaccine Trial Group Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised … PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... Lancet 396 (10249), 467-478, 2020 | 68 | 2020 |
| Interferon-gamma release assays for tuberculosis: current and future applications M Thillai, K Pollock, M Pareek, A Lalvani Expert Review of Respiratory Medicine 8 (1), 67-78, 2014 | 68 | 2014 |
| COVID-19 Genomics UK consortium; AMPHEUS Project KRW Emary, T Golubchik, PK Aley, CV Ariani, B Angus, S Bibi, B Blane, ... Oxford COVID-19 Vaccine Trial Group. Efficacy of ChAdOx1 nCoV-19 (AZD1222 …, 2021 | 52 | 2021 |
| COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre … JL Alexander, Z Liu, DM Sandoval, C Reynolds, H Ibraheim, ... The Lancet Gastroenterology & Hepatology 7 (11), 1005-1015, 2022 | 43 | 2022 |
| PD-1 Expression and Cytokine Secretion Profiles of Mycobacterium tuberculosis-Specific CD4+ T-Cell Subsets; Potential Correlates of Containment in HIV-TB Co … KM Pollock, DJ Montamat-Sicotte, L Grass, GS Cooke, MS Kapembwa, ... PloS one 11 (1), e0146905, 2016 | 42 | 2016 |
| Redefining latent tuberculosis S Sridhar, K Pollock, A Lalvani Future Microbiology 6 (9), 1021-1035, 2011 | 31 | 2011 |
| Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV A Ogbe, M Pace, M Bittaye, T Tipoe, S Adele, J Alagaratnam, PK Aley, ... JCI insight 7 (7), 2022 | 30 | 2022 |
| Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support–free days in patients hospitalized with COVID-19: a randomized … S Florescu, D Stanciu, M Zaharia, A Kosa, D Codreanu, K Fareed, ... Jama 329 (14), 1183-1196, 2023 | 27 | 2023 |
| Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA. 1 and BA. 4/5 variants in patients with inflammatory bowel disease treated with infliximab and … Z Liu, K Le, X Zhou, JL Alexander, S Lin, C Bewshea, N Chanchlani, ... The Lancet Gastroenterology & Hepatology 8 (2), 145-156, 2023 | 24 | 2023 |
